CA1207230A - Topical preparation for treating herpes simplex virus - Google Patents

Topical preparation for treating herpes simplex virus

Info

Publication number
CA1207230A
CA1207230A CA000422625A CA422625A CA1207230A CA 1207230 A CA1207230 A CA 1207230A CA 000422625 A CA000422625 A CA 000422625A CA 422625 A CA422625 A CA 422625A CA 1207230 A CA1207230 A CA 1207230A
Authority
CA
Canada
Prior art keywords
topical preparation
preparation
heat
oil
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000422625A
Other languages
French (fr)
Inventor
Harvey T. Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA000422625A priority Critical patent/CA1207230A/en
Application granted granted Critical
Publication of CA1207230A publication Critical patent/CA1207230A/en
Expired legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

ABSTRACT
The topical preparation comprises a stable emulsion having from approximately 30% by volume to approximately 50% by volume of anhydrous ethyl ether in a pharmaceutic-ally acceptable coconut oil carrier having most of the free fatty acids thereof removed, said emulsion having a boiling point of at least 100°F. The topical preparation is used in a method for treating, in vivo, an epidermal area of a human being infected with Herpes simplex virus by applying to the infected area in an amount sufficient to cover the infected area the topical preparation. Prefer-ably, heat is also applied to the infected area shortly after the topical preparation is applied, e.g., heat is applied for a period of between 3 and 15 minutes approx-imately three minutes after the topical preparation is applied.

Description

~7~3~

TOPICP.L PREPARATION FOR TREATING HERPES SIMPLEX VIRUS
Technical Field The present invention relates to a method for txeat-ing Herpes simplex virus and to a top$cal preparation for application to areas of the human body infected by ~erpPs simplex virus for inactivating the virus.

Background Art There are two types of Herpes simplex vlrus which produce a variety of clinical manifestations. In general, Herpes simplex type 1 is associated with recurrent labial-i5 scold sores and Herpes simplex type 2 is associated with recurrent vulvovaginitis.
Herpes simplex virus appears to find the spongy area around mucus membranes an attractive place to thrive and cause infectivity. Once the integrity of an area is violated by Herpes simplex virus, there seems to be a triggering mechanism that welcomes repeated infection of the same area The reason for this phenomenon occurring is not known at present.
Herpes simplex virus infectivity is primarily de-pendent upon the intactness of the viral envelope and a chemical combination which damages or removes the envelope will reduce infectivity greatly. It is well known that ether is extremely successful in producing this effect.
However, the normal body temperature is about 4C above the boiling point of ethyl ether such that treatment in vivo heretofore has not been successful. See for example "Topical Ether and Hexpes Simplex Labialis" by Mary E.
Guinan, M.D., Ph.D., et al. JAM, March 14, 1980, Vol. 2~3, No. 10, pp. 1059-61. Also, due to the extxeme instability of ether, particularly ethyl ether, at room temperature or higher ethyl ether has heretofore only been used for this type of treatment in a controlled environment such as a hospital or physician's office, and ethyl e~hex has not been available in a form sultable for use outside of a controlled (e.g., hospital) environment.
2 ~Z~3~
Rather, ether-, amide-, or ester-linkage compounds, alone or in combination, have been used. However, the effectiveness of such compounds in treating Herpes simplex virus is far lest thin that of a pure ether. An example of an emulsion including such a compound is disclosed in the Asculai et alO U.S. Patent No. 4,020,183.
According to the teachings of this patent, non-ionic surfactants are delivered in a non-irritating car-rier such as a lotion or oil to an infected area with the amount of surfactant employed being between 0.5% and 20 by volumeO
It has also been proposed in Alnor U.S. Patent No.
3,949,071 to use an aqueous solution including a base, fatty acids comprising primarily oleic acid, and a surface-active agent for treating burns, scalds and other skin ir-rita~ions. The base is an alkali metal carbonate.
Further it has been proposed in Grove U.S. Patent No. 2,0~9,166 to use a topical preparation of a soft soap and stearoptens in a salve for use as a liniment.
Still further it is known from "A simple proof of the thermodynamic stability ox materials taken up by solu-tions containing solubilizers such as soup", Amer. Chem.
Soc. 62, 2855-9 (1940) that ether is thermodynamically stable in soap. More specifically, the colloidal solutions formed from a solution of ther and soap containing small additions of silicate or hydroxide are thermodynamically stable because the vapor pressure is significantly less than that of the free hydrocarbon until the solution is approximately saturated.
Moreover, it is known from SOAP MANUFACTURE by J.
Davidsohn, et al. published by Interscience Publishers, Inc.
New York, p. 495, that coconut oil soap was germicidally more active against Escherichia coli and Eberthella typhosa than other soaps made from natural fats and oils. Also, this text teaches at page 503 that coal tar soaps can be made by adding wood tar to coconut oil soap and at page 505 that sulphur soap can be made by adding sulphur to coconut oil soap.
I

3 23~
As will be descried in greater detail hereinafter, the method and topical preparation of the present invention differ from the previously proposed method and preparations in that according to the method of the preen inventlon topical preparation comprising an emulsion of anhydrous ethyl ether (rather than a linkage compound) wherein the amount of anhydrous ethyl ether used comprises at least 30% by volume of the emulsion and a coconut oil caxrier is applied to the infected area. Also, the emulsion uses a coconut oil carrier having a minimum of free fatty acids.
Additionally, the method preferably includes the step of subsequently applying heat to the infected area.

7~

DISCLOSURE OF INVENTION
According to the invention there is provided a topical preparation for treating an epidermal area of a human being infected with Herpes simplex virus character-ized by comprising a stable emulsion havinq from approx-imately 30~ by volume to approximately 50% by volume of anhydrous ethyl ether in a pharmaceutically acceptable oil carrier having most of the free fatty acids thereof removed, said emulsion having a boiling point of at least 100F.
Further according ot the invention there is provi-ded a method for treating in vivo an epidermal area of a human being infected with Herpes simplex virus charac-terized by comprising the step of applying to the infec-ted area in an amount sufficient to cover the infectedarea a topical preparation including a stable emulsion having from approximately 30~ by volume to approximately 50~ by volume of anhydrous ethyl ether in a pharmaceut-tally acceptable oil carrier having most of the free fatty acids removed, said emulsion having a boiling point of at least 100F.
Preferably, heat is applied to the infected area shortly after the topical preparation is applied, e.g., heat is applied for a period of between 3 and 15 minutes approximately three minutes after the topical preparation is applied.
Preferably, the pharmaceutically acceptable oil carrier is coconut oil.

I"

Z3~
BEST MODE FOR CARRYING OUT THE INVENTION
In accordance with the teachings of the present in-vention, a topical preparation including an emulsion of anhydrous ethyl ether end a coconut oil carrier having most of the free fatty acids removed has been found to be useful in treating epidermal areas infected with Herpes simplex virus.
According to the method of the present invention a stable emulsion of at least 30~ by volume of anhydrous ethyl ether in a pharmaceuticallv acceptable coconut oil carrier with most of the free fatty acids removed is ap-plied to the infected area. Preferably, heat is also ap-plied to the infected area some time after the application of the topical preparation for a period of 3 to 15 minutes.
l It has been known for some time that ethyl ether is very helpful in treating the "cold sore" lesion in an epi-dermal area infected by Herpes simplex virus. In this re-spect~ the ether damages or removes the viral envelope thereby reducing infectivity. However, ether, particularly ethyl ether, is extremely unstable and has a very low boil-ing point. Accordingly, one must be very careful in apply-ing ethyl ether and in the past this has only been done in a controlled environment such as in a hospital outpatient ward or in a physician's office. Also, the ethyl ether evaporates quickly and as a result does not penetrate deep-ly into the infected area.
In view of the rapid evaporation of ether, it has been proposed in U.S. Patent NoO 4,020,183 to apply an ether-linkage compound in a non-irritating carrier such as a lotion or oil to the infected area. In this way the ether-linkage compound in the carrier can be maintained on the infected area for a significant period of time to allow penetration by the ether-linkage compound. However, the ekher~linkaga compound iB no as strong and efective as ethyl ether in destroying the viral envelope.
Ihus, according to the teachings of the present in-vention, anhydrous ethyl ether which is a highly volatile chemical, is utilized. However, it must be combined with 6 ~2~3~
a carrier so that it will be more stable. Anhydrous ethyl ether is used because it is believed to afford deeper pene-tration than other ethers or ether linkage compounds hav-ing a higher boiling point. Also, ethyl ether is more S readily available for use in the anhydrous form than are other ethers such as methyl ether, which has a lower boil ing point. Anhydrous ethyl ether has virtually no (0 01%) waxer. Thus, by using anhydrous ethyl ether, the infeo~ed area is kept as dry as possible. In this respect, moistuxe appears to be a d~terent to the healing process of the "cold sore" lesion in an area infected with Herpes simplex virus when applying ether thereto.
The anhydrous ethyl ether utilized in the method of the present invention has the following American Chemical 5 Society specifications:
Butylated Hydroxy-toluene (preservative) 0.5-1 ppm Assay (C2H5)2 o by CC 98.5%
Color (APHA) 10 Density (gm/ml at 25C Max) .7079 20 Peroxide (as H202) .0001 Residue after evaporation .001 Substances darkened by H2S04 Passable Alcohol (C2H50H) .01%
H20 (Karl Fisher) .01 ~5 Trace I~lpurities PPM
Acid (as CH3C00~) .5 Copper .1 Heavy metals (A5PB~ .1 Nickel (Nlj .1 Further according to the teachings ox the present invention, coconut oil with most of the free fatty acids removed is used as the carrier. Although other natural oils could be used, coconut oil was found to be the most suitable for emulsification with the anhydrous ethyl ether.
The coconut oil can be refined and bleached or hydro-genated.

7Z3~
The refined and bleached or hydrogenated coconut oil carrier is obtained in the following manner:
First, coconut oil is refined with caustic soda (NaOH), this process also being known as refining of a glyceride. Here the natural oil (a glyceride) is broken down into glycerol and a soap containing most (at least 95~) of the free fatty acids. The glycerol is .retained and this process of removing free fatty acids found in the oil (i.e., palmitic, capric, oleic, linoleic and lino-lenic acids) makes the carrier much less irritating tothe skin. The oil now contains no more than 7~ free fat-ty acids and preferably between 2.5 and 3.5% free fatty acids. It is believed that the refined coconut oil car-rier aids in healing the epidermal area around the "cold sore" lesion, which area has been leached of moisture by the anhydrous ethyl ether applications, by sealing that epidermal area to air and water which can be deterents to the healing process.
After the refining, the glycerol is further pro-cessed, i.e., it can be hydrogenated, to produce stearic acid (cold cream) and the desired product, refined and hydrogenated coconut oil, the carrier used in the emulsion with the anhydrous ethyl ether. It has been found empir-ically that the most suitable refractive index of hydro-25 genation for the carrier is 1.4540 0.0002 at 25C and aniodine value of 4 5 0.5.
Refining and hydrogenation of oils are well known processes and the manner in which these processes are carried out is described in the text entitled: Official and Tentative Methods of the Americ _ Oil Chemist's Society (3rd Ed.) 1976, published by the American Oil Chemist's Society, Champaign, Ill. In this text, refining of oil techniques are described in A.O.C.S. Official Method Cc 8d-55 pages 1-3 and hydrogenation of oil techniques are described in A.O.C.S. Recommended Practice Ca 17-~6 pages 1-3.

.

8 ~2~2~0 This hydrogenation process is believed to 510w down the development of rancidity of the oil, a common problem of oil based compounds and thus allows a longer shelf and use life.
Refined and bleached or hydroyenated coconut oil which has an iodine value of 4.5 0,5, which has no more than 7% free fatty acids (FFA as oleic) and which has a refractive index of 1.4540 1 0.0002 at 25~C is commercial-ly available from:
CPC International International Plaza P.O. Box 500 Englewood Cliffs, N.J., frQm its subsidiary sest Foods CPC International 2841 S. Kilbourne Chicago, Illinois and from-Capital City Products 1200 Route 46 W. New York, N.J.
One preferred partially hardened refined and bleached (or hydrogenated) coconut oil had the following material specifications:
Color (Lovibond) Max. 4.0 Red F.F.A. (as oleic) Max. 7.0 M~I.U. (Moisture Inert:Dist) Max. 1.0 Saponification value Min. 254 (1) Polyunsaturated Acids Max. 0.40%
Iodine Value 4.5 + 0.5 Odor Usual characteristic odor refractive index 1~4540 0.0002 (lo To be determined by using A.O.C.S. Method Cd 7-58 In the refining of the coconut oil, the free fatty acids are taken off, i.e., the free fatty acids are conver-ted to soap which settles and are taken off as "foots"
with glycerols of other fatty acids retained, I
the glycerols C6 to Cl8. The hydrogenation thus chan-ges the unstable glycerols, e.g., oleic (unstable to ste-~7~

aric (stable).
Coeonut oil is a mixture of fatty acids of evennumber mole~ulte~ C6 through cl8_1~ The amount ox C6 and C20 are nil.
The distribution is as follows:
Fatty Acid %
C6 ~Caproic) Nil C8 (Caprylic) 6+1 C10 (capric) 7+1 10 C12 Laurie 48. 5+10 5 C14 (Myristic~ 19.0il.0 C16 (Palmitic) 8.75~ 0.75 C18 tstearic) 5.25+ 0.75 C18_1 (Oleic) 3.00~ 0.50 15 The free fatty acids in the coconut oil will sapon-ify under certain conditions during the refining of the crude coconut oil while tha other components will not.
For example, in one refining process, 500 gm of crude coconut oil is put into a water bath with a mechani-cal stirrer at a temperature between 30-35C at 250 RPM.
Next an amount of ~0 Baume NaOH is added to effectively saponify the free fatty acids, e.g., C17Il33COO~ (oleic acid + NaOH = C17H33COONa -I H2O. The molecular weight ox the oleic acid is 282.4 and the molecular weight of the sodium hydroxide is 40.
After the amount of NaOH is determined by conven-tional calculations, it is added to the water bath which is then stirred for 5 minutes. Next, decrease speed to 70 RPM and raise the temperature of the water bath quick-ly to 50-53C. Stir for 10-15 minutes more or until the "foots" (bottom soap) appeax to be ready to settle out.
Let sit in bath until oil is relatively clear before re-moving the refined oil.
In bleaching the refined coconut oil, a 60 mush screen, bleaching earth as per American Oil Chemists '7~3~

Society standards,filter paper (Sargent Welch Grade S 32915-J or equivalent) and rolled cotton are used.
The screen is lined with thin layers of rolled cotton and 300 gm of refined oil are allowed to filter into a stainless steel cup which is then placed under a mechan-ical stirrer. Then, 9 grams of bleaching earth are added and stirred at a temperature of 100 Jo 110C. The speed of stirring is fast enough to keep the bleach in suspen-sion for five minutes. Next the solution is filtered through a steel funnel having the filter paper therein and the filtrate of refined and bleached coconut oil is col-lected in a beaker.
The emulsion of anhydrous etheyl ether and the hy-drolyzed and hydrogenated coconut oil or the refined and bleached coconut oil is combined in a ratio of from 1:2 to 1:1, anhydrous ethyl ether by volume to coconut oil by volume with a ratio of 2.3 being preferred.
From numerous tests it was found that by combining the coconut oil with the anhydrous ethyl ether in a ratio of 3:2 by volume, forming thereby a supersaturated emul-sion, the normal boiling point of the emulsified ethyl ether is raised to approximately 119F. This numerical ratio combination of the oil and ether was also observed to produce the least amount of damage, i.e., necrosis, of the viable tissue surrounding the herpetic lesion, while still providing a highly effective agent in destroying the viral envelope.
The emulsion is applied as a topical preparation to the infected area or areas in an amount sufficient to cov-er the infected area or areas once a day for a period offrom one week up to ninety days, if necessary. Empirical measurements indicate that the amount applied is approxi mately one cubic centimeter (1 cc1 for approximately each each 1/4 square inch ~0.4 square centimeter) ox in~cted surface area. More specifically, the preparation is ap-plied daily until the "cold sore" lesions in the infected area are no longer visible.

3~
Preferably, heat is also applied Jo the infected area, and it has been observed that the heat application appears to speed up and assist the healing process, i.e., the disappearance of the "cold sore" lesions.
Two types of heat ha been used with goods results.
One is radiant, infra-red or dry heat and the other is wet heat applied with a hot, wet towel.
The radiant, infra-red heat is applied at a temper-ature as high as the patient can withstand for a period of lS to 20 minutes on the morning after the preparation is applied. The infra-red source is positioned 16 inches or rnore from the infected area on the patient's face with a mask provided over the adjacent facial area, particular-ly over the eyes, to protect them The radiant heat ap-pears to assist in drying the lesions and was found to bevery effective in drying multiple eruptions.
It is also believed that thP application of heat in-creases the blood supply to the area of infection and in-creases oxygenation of the tissue in that area so as to aid healing further. Also, increased blood flow caused by application of heat is believed to promote a more rapid removal of the debris left behind as the lesion is destroyed.
As an alternative to infra-red heat, wet heat in the form of hot, wet towels can be applied to $he infec-ted area at a temperature as high as the patient can with-stand, for a period of 15 to 20 minutes each morning and each evening with the topical preparation being applied only once a day in the evening.
For individuals subject to multiple infections at regular intervals, the topical preparation is applied three times daily for the first five days followed by applica-tion of the topical preparation three times a day for the next five days with each such application being followed by application of a hot, wet towel (as hot as the indiv-idual can stand) for 3 to 20 minutes three times a day.

12 3~
In one method of treatment, about 2 cc of the top-ical preparation is applied to the infected area around, for example, the lipsD After tnree minuteC~ a wet towel, as hot as is bearable by the patient, is applied to the area for about the minute.
It is believed that without heat the ether pene-trates the infected area as deeply as possible in about three minutes. Then it is believed the heat from the wet towel causes the ether what has penetrated to vaporize allowing it to propel or move up the "trigeminal canal", killing the viruses that hide there in a dormant state and become active later causing recurrent infections.
Again, it is believed that about three minutes is a suffi-cient time to keep the vapors moving in the canal at a suf-ficient pressure and volume to destroy the virus.
Empirical studies show that one method of treatmentis to apply the topical preparation at least once (prefer-ably twice) a day for three days. Then, on the third day, even if the "cold sore" appear to be "cured", the prepar-ation ancl heat as described above are applied three timesa day for at least three days. It is believed that after this period the medication has "won the fight" in killing the virus at the site of infection and the body's immune system can take over the "battle" forcing the virus to escape via the trigeminal canal.
I~o individuals who had had on the average one "cold sore" per year during thy two years prior to treatment with the method of the present invention were treated with a topical preparation which comprised 60% by volume coconut oil with most of the fatty acids removed and 403 by volume anhydrous ethyl ether and which was applied to the infected area once a day for seven days together with application of radian, infra-red heat once a day on the morning after application of the topical preparation. No recurrence of the "cold sore" lesion was observed for a period of seven years after this treatment.
Eight individuals who had had on the average four "cold sore" lesions per year during the ten year period ,, 3~

prior to treatment with the method of the present inven-tion were treated with a topical preparation which com-prised 60~ by volume coconut oil with most of the fatty acids removed and 40% by volume anhydrous ethyl ether s and which was appiied to the infected area once a day for ninety days together with applicat:ion of wet heat by means of hot, wet towels twice a day for ninety days. Sub-sequent to this treatment, no recurrence of the "cold sore"
lesions was observed for a period of 2 1/2 years after treatment. The severity of infection with these individu-als was such that on the average two of the four appear ances of "cold sore" lesions were multiple lesions.
Another four individuals who had had on the average five "cold sore" lesions per year during the ten years pre-ceeding treatment with the method of the presetn inventlonwere treated with a topical preparation which comprised 60~ by volume of coconut oil with most of the fatty acids removed and 40% by volume of anhydrous ethyl ether and which was applied to the infected area once a day for nine-ty days toge-ther with application of wet heat by means of hot wet towels twice a day for ninety days. The severity of the infection with these individuals was such that on the average four out o five appearances of the "cold sore"
lesions were multiple lesions. No recurrence of the "cold sores" was observed in these individuals for a period of two years after treatment.
Still another ten individuals who had had on the average two "cold sore" lesions per year during the ten years prior to treatment with the method of the present in-vention were treated with a topical preparation which com-prised 60~ by volume of coconut oil with most of the fatty acids removed and 40% by volume of anhydrous ethyl ether and which was applied to the infected area once a day for twenty days together with application of wet h2at by means of hotl wet towels twice a day for twenty days. Subsequent to this treatment, no recurrence of the "cold sore" lesions was observed for a period of two years after treatment.
It will be appreciated that with the topical prepar-14 ~2~7~ation of the present invention a safe means of delivering ethyl ether to an epidermal area infected with Herpes simplex virus is made possible. In this xespect~ the anhydrous ethyl ether is emulsified in the refined and bleached coconut oii carrier as described above so that the heat instability of the anhydrous ethyl ether is counteracted by the high boiling point of the coconut oil carrier. In this way, the boiling point of the over-all emulsion is raised from the normal boiling point of ethyl ether at 34.6C (approximately 87~F) up to approx-imately 54.4C (approximately 119F). This increase in the bioling point of anhydrous ethyl ther in the emul-sion enables the ethyl ether in the emulsion to be stored more easily and more safely thereby to permit its use out-side of the controlled environment of a hospital out-patient clinic or a physician's office.
Also it will be appreciated that by utilizing ap-plications of heat to the infected area in addition to the application of the topical preparation healing of the "cold sore" lesions is enhanced and expedited. As stated above, it is believed this is caused by the increase in blood flow to the infected area as a result of the heat applied thereto.
Another important feature of the present invention is that by using at least 30% by volume of anhydrous ethyl ether in a refined and bleached coconut oil carrier, as op-posed to an ether-linkage compound, a stronger agent is used in the treatment of Herpes simplex virus thereby to provide a more effective treatment. In this respect, the anhydrous ethyl ether is more effective than the ether-linkage compounds in destroying the viral envelope of Herpes simplex virus thereby to prsvide a more effective treatment. In this respect, the anhydrous ethyl ether is more effective than the ether-linkage compounds in de-35 stroying the viral envelope and the emulsion enables oneto apply a sufficient volume of ethyl ether to the infec-ted area. Moreover, by using anhydrous ethyl ethex, vir-tually no water is placed in contact with the infected 723~
area when the ether is applied thereby to aid further the healing process.
Another advantage of the topical preparation of the present invention is the use of refined and bleached coco-nut oil which has much of the skin irritating tree ~attyacids removed therefrom. Moreover, the refined and bleached coconut oil carrier serves to protect the infect ted area during treatment thereof fro~l air and water which are often deterents to the healing process.
From the foregoing description it will be apparent that the method and topical preparation for treating Herpes simplex virus of the present invention have a num-ber of advantages some of which are described above and others of which are inherent in the invention For exam-ple, it has been observed that in treating a cold sore vi.rus according to the teachings of the method of the pres-ent invention and utilizing the topical preparation of the present invention, local recurrence of cold sores is great-ly minimized if not altogether eliminated, and such preven-tion oE recurrence is greatly desired when treating Herpessimplex virus infectivity.
Moreover, from empirical tests it has been found that the topical preparation applied according to the methods of the present invention is effective in treating in vivo Herpes I, Herpes II, "athlete's foot" fungus, "jock itch" fungus and yeast infections and may be effec-tive in treating Chicken Pox, Acne, Eczema, occlusions and infections of pores tpimples and blackheads3, skin rashes and canker sores.

Claims (20)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A topical preparation for treating an epidermal area of a human being infected with Herpes simplex virus comprising a stable emulsion having from approximately 30% by volume to approximately 50% by volume of anhydrous ethyl ether in a pharmaceutically acceptable oil carrier having most of the free fatty acids thereof removed, said emulsion having a boiling point of at least 100°F.
2. The topical preparation of claim 1 wherein said oil is refined to have no more than 7% free fatty acids.
3. The topical preparation of claim 2 wherein said oil is hydrogenated.
4. The topical preparation of claim 3 wherein the refractive index of said hydrogenated oil is 1.4540 ? 0.0002 at 25°C
5. The topical preparation of claim 3 wherein the iodine value of said hydrogenated oil is 4.5 ? 0.5.
6. The topical preparation of claim 1 wherein said oil is refined and bleached oil.
7. The topical preparation of claim 1 wherein the boiling point is approximately 119°F.
8. The topical preparation of claim 7 wherein the boiling point is approximately 119°F.
9. The topical preparation of claim 1 wherein said emulsion is supersaturated.
10. The topical preparation of claim 1 wherein said pharmaceutically acceptable oil carrier is coconut oil having most of the free fatty acids removed therefrom.
11. The topical preparation as claimed in claim 1 for use in combination with a subsequent application of heat to the epidermal area.
12. The topical preparation as claimed in claim 11 wherein the heat is wet heat.
13. The topical preparation as claimed in claim 12 wherein the heat is applied about three minutes after the preparation is applied and for about three minutes.
14. The topical preparation as claimed in claim 13 wherein applications are made three times per day for at least three days.
15. The topical preparation as claimed in claim 12 wherein the heat is only applied on the third day following an application of the preparation and after two days of applying the preparation three times daily, followed by applying the preparation three times per day for at least three more days with wet heat applications about three minutes later for about three minutes.
16. The topical preparation as claimed in claim 12 wherein the preparation is applied once a day and the wet heat is applied for about 15 minutes every morning and evening for a period of at least three weeks.
17. The topical preparation as claimed in claim 12 wherein the preparation is applied once a day and the wet heat is applied twice a day until the infection clears.
18. The topical preparation as claimed in claim 11 wherein the heat applied is radiant heat from an infrared heat source.
19. The topical preparation as claimed in claim 18 wherein the radiant heat is applied for about 15 minutes every morning for at least one week.
20. The topical preparation as claimed in claim 18 wherein the preparation is applied once daily until infection clears.
CA000422625A 1983-03-01 1983-03-01 Topical preparation for treating herpes simplex virus Expired CA1207230A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000422625A CA1207230A (en) 1983-03-01 1983-03-01 Topical preparation for treating herpes simplex virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000422625A CA1207230A (en) 1983-03-01 1983-03-01 Topical preparation for treating herpes simplex virus

Publications (1)

Publication Number Publication Date
CA1207230A true CA1207230A (en) 1986-07-08

Family

ID=4124685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000422625A Expired CA1207230A (en) 1983-03-01 1983-03-01 Topical preparation for treating herpes simplex virus

Country Status (1)

Country Link
CA (1) CA1207230A (en)

Similar Documents

Publication Publication Date Title
US5662921A (en) Therapeutic uses of emu oil
ES2310010T3 (en) VISCOSE COMPOSITIONS CONTAINING CARBON DIOXIDE.
US4707293A (en) Detergent composition
US2492085A (en) Aluminum chlorohydrate astringent
WO1998033471A1 (en) Non-irritating composition for treating acne and other skin conditions
JPH0148885B2 (en)
HU185936B (en) Process for producing pharmaceutical composition for topical treating virus-infestions of skin and mycoderm
US5268176A (en) Method and compositions for the non-invasive treatment of telangiectasia
EP0225367B1 (en) Film forming composition for topical use
CA1207230A (en) Topical preparation for treating herpes simplex virus
JPH05229916A (en) Gel-like cleanser composition
EP0102410B1 (en) Topical preparation for treating herpes simplex virus
JPS5517328A (en) Insulin-containing emulsion and its preparation
US4657933A (en) Topical preparation and method for treating Herpes simplex virus infection
US4657934A (en) Method for treating Herpes simplex virus infection and topical preparation used therein
US2001046A (en) Medicinal preparation
JP2002524418A (en) Ophthalmic compositions and uses
US5837227A (en) Use of cocoa butter or partially hydrolyzed cocoa butter for the treatment of burns and wounds
JPS60193915A (en) Local medicine for treating human scarf-skin area
JP3513861B2 (en) External preparation for skin
JPH05500661A (en) new formulation
US2914442A (en) Novel otologic preparations and the process for their preparation
RU2072849C1 (en) Composition for varicose vein treatment and method of its preparing
CA2514381A1 (en) Improved topical preparation and method for using same to destroy herpes simplex cells
JP3479402B2 (en) Bath composition

Legal Events

Date Code Title Description
MKEX Expiry